This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Women's Health, Other  • Alert me on articles by topic

Joan Stephenson, PhD

JAMA. 2007;297:2578.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Gardasil, a human papillomavirus (HPV) vaccine that targets 2 HPV strains that cause about 70% of cervical cancers, is more effective in preventing precancerous cervical lesions in women who have not been previously exposed to HPV than in those already infected with the virus, according to findings by an international team of scientists (FUTURE II Study Group. N Engl J Med. 2007;356:1915-1927).

In the study, funded by the vaccine's manufacturer, Merck & Co (Whitehouse Station, NJ), 12 167 women aged 15 to 26 years were randomized to receive either the vaccine or placebo. At baseline, 93% of the women were already sexually active and 27% had been infected by at least 1 HPV strain.

The women were followed up for an average of 3 years and the researchers found that the vaccine significantly reduced the risk of HPV-16–related or HPV-18–related lesions (grade 2 or 3 cervical epithelial . . . [Full Text of this Article]